Vascular Medicine Research Unit, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Trends Pharmacol Sci. 2011 Mar;32(3):167-73. doi: 10.1016/j.tips.2010.12.006. Epub 2011 Jan 16.
ROCKs are important regulators of the actin cytoskeleton. Because changes in the actin cytoskeleton underlie vascular contractility and remodeling, inflammatory cell recruitment, and cell proliferation, it is likely that the Rho/ROCK pathway will play a central role in mediating vascular function. Indeed, increased ROCK activity is observed in cerebral and coronary vasospasm, hypertension, vascular inflammation, arteriosclerosis, and atherosclerosis. Recent experimental and clinical studies suggest that inhibition of ROCK could be a promising target for the treatment of cardiovascular disease. For example, inhibition of ROCK might be the underlying mechanism by which statins or HMG-CoA reductase inhibitors exert their therapeutic benefits beyond cholesterol reduction. In this review we summarize current understanding of the crucial role of RhoA/ROCK pathway in the regulation of vascular function and discuss its therapeutic potential in the treatment of atherosclerosis and vascular disease.
ROCKs 是细胞骨架肌动蛋白的重要调节因子。由于细胞骨架肌动蛋白的变化是血管收缩性和重塑、炎症细胞募集和细胞增殖的基础,因此 Rho/ROCK 途径很可能在调节血管功能方面发挥核心作用。事实上,在脑和冠状血管痉挛、高血压、血管炎症、动脉硬化和动脉粥样硬化中都观察到 ROCK 活性增加。最近的实验和临床研究表明,抑制 ROCK 可能是治疗心血管疾病的一个有前途的靶点。例如,抑制 ROCK 可能是他汀类药物或 HMG-CoA 还原酶抑制剂除了降低胆固醇之外发挥治疗益处的潜在机制。在这篇综述中,我们总结了 RhoA/ROCK 通路在调节血管功能中的关键作用的最新认识,并讨论了其在治疗动脉粥样硬化和血管疾病中的治疗潜力。